TIDMHCM

RNS Number : 1450S

Hutchison China Meditech Limited

07 July 2020

Notification of Dilution of Voting Rights

London: Tuesday, July 7, 2020 : Hutchison China MediTech Limited ("Chi-Med") (Nasdaq/AIM: HCM) was notified that CK Hutchison Holdings Limited (" CK Hutchison ") shareholding(1) in Chi-Med remains unchanged, at 332,478,770 ordinary shares of par value US$0.10 each in the capital of Chi-Med ("Shares").

Each American Depositary Share ("ADS") represents five Shares. As announced on June 25, 2020, Chi-Med issued a total of 20,000,000 Shares (equivalent to 4,000,000 ADSs) to General Atlantic . Chi-Med was notified on July 6, 2020 that this issuance diluted CK Hutchison's holding(1) to 46.79 per cent of the total number of voting rights of Chi-Med. The date on which the notification threshold was crossed was July 3, 2020.

About CK Hutchison

Listed on The Stock Exchange of Hong Kong Limited, CK Hutchison is a renowned multinational conglomerate committed to innovation and technology with businesses spanning the globe. With operations in about 50 countries and over 300,000 employees worldwide, CK Hutchison has five core businesses - ports and related services, retail, infrastructure, energy and telecommunications.

CK Hutchison reported turnover of approximately HK$440 billion (US$56 billion) for the year ended 31 December 2019.

For more information, please visit www.ckh.com.hk.

About Chi-Med

Chi-Med (Nasdaq/AIM: HCM) is an innovative biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has a portfolio of eight cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. For more information, please visit: www.chi-med.com.

([1]) Held through CK Hutchison's indirect wholly-owned subsidiary Hutchison Healthcare Holdings Limited.

CONTACTS

 
Investor Enquiries 
  Mark Lee, Senior Vice President                            +852 2121 8200 
  Annie Cheng, Vice President                                +1 (973) 567 3786 
 
Media Enquiries 
  Americas - Brad Miles, Solebury Trout                      +1 (917) 570 7340 (Mobile) 
                                                              bmiles@troutgroup.com 
  Europe - Ben Atwell / Alex Shaw, FTI Consulting            +44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 
                                                             545 055 (Mobile) 
                                                             Chi-Med@fticonsulting.com 
  Asia - Joseph Chi Lo / Zhou Yi, Brunswick                  +852 9850 5033 (Mobile), jlo@brunswickgroup.com / +852 97 
                                                             83 6894 (Mobile), y zhou@brunswickgroup.com 
 
Nominated Advisor 
  Freddy Crossley / Atholl Tweedie, Panmure Gordon (UK) 
   Limited                                                   +44 (20) 7886 2500

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

TVRUNVRRRKUBRAR

(END) Dow Jones Newswires

July 07, 2020 02:00 ET (06:00 GMT)

Hutchison China Meditech (LSE:0J7G)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Hutchison China Meditech Charts.
Hutchison China Meditech (LSE:0J7G)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Hutchison China Meditech Charts.